← Eichor
Study identifier: NCT06517979 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis

Condition: Cancer · Lymphatic Metastasis  ·  Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

PhaseN/A
Planned participants10000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this diagnostic test is to develop an artificial intelligence (AI)-based pan-cancer universal diagnostic model for detecting pathological lymph node metastasis (LNM), and prospectively evaluate its apllication value in the real-world clinical practice. Investigators will compare the diagnostic performance (sensitivity, specificity, etc.) of the AI model and routine pathological report issued by pathologists, to see if the AI model can improve the clinical workflow of pathological evaluation of cancer LNM in in the real world.

This description comes directly from the study's public registry record.

Talk to the study team

Lin Tianxin, Ph.D  ·  13724008338, China  ·  lintx@mail.sysu.edu.cn

Wu Shaoxu, MD  ·  15017581087, China  ·  wushx29@mail.sysu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen Memorial Hospital of Sun Yat-sen UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06517979